Skip to main content

Table 1 Summary of clinical studies conducted using bone marrow-derived mesenchymal stem cells in patients with osteoarthritis

From: Mesenchymal stem cells for cartilage repair in osteoarthritis

Study

number

Authors or

institution

Number

of

subjects

Type of

study

Cell type and

dose used

Efficacy parameters

Outcome

Duration offollow-up

Referenceor Clinical-Trials. govidentifier

1

Kuroda et al., 2007

[40]

1

Case report

Autologous BM-MSCs

+ collagen gel

Arthroscopy and HPE

Defect filled with hyaline-like type of cartilage tissue

1 year

[40]

2

Wakitani et al.,

2007 [41]

3

Case series

Autologous BM-MSCs

(5 million) + collagen sheet

HPE and MRI

Histology: defect repaired with fibrocartilaginous tissue

MRI: complete coverage of defect

1 year

[41]

3

Osiris

Therapeutics, Inc.

(Columbia, MD,

USA), 2007

55

Randomized

double-blind

Allogeneic BM-MSCs

(50 and 150 million)

VAS pain score and MRI

VAS: Significantly reduced pain

MRI: Decreased degenerative bone changes

2 years

[46, 47]

4

Centeno et al.,

2008 [45]

1

IRB-approved

study

Autologous BM-MSCs (22.4 million) + 1 mL of nucleated cells + 1 mL of 10% platelets

VAS pain score and MRI knee joint

Decreased VAS score

MRI: increase in meniscus and femoral cartilage volume

24 weeks

[45]

5

Nejadnik et al.,

2010 [39]

72

Observational

cohort study

Autologous BM-MSCs:

n = 36; Chondrocytes:

n = 36

ICRS Cartilage Injury

Evaluation Package

Improvement in physical role functioning in BM-MSCs

2 years

[39]

6

Davatchi et al.,

2011 [44]

4

IRB-approved

study

Autologous BM-MSCs

(8 to 9 million)

Walking time for the pain to

appear and VAS pain score

Walking time for pain improved in 3 patients

VAS decreased in all patients

1 year

[44]

7

Haleem et al., 2012

[42]

5

Case series

Autogous BMSCs

placed on platelet-rich

fibrin glue

RHSSK scores and MRI

Improvement in RHSSK score and subjective symptoms

MRI: complete defect fill and complete surface congruity

with native cartilage

1 year

[42]

8

Kasemkijwattana

et al., 2011 [43]

2

Case report

Autologous BMSCs

(12 million)

KOOS, IKDC score, and

arthroscopy

Improvements in KOOS and IKDC score

Arthroscopy: Good defect fill, stiffness, and incorporation

to the adjacent cartilage

30-31 months

[43]

9

National University

of Malaysia/

Cytopeutics

(Malaysia)

50

Randomized

controlled

Autologous BMSCs

VAS, IKDC Subjective Knee

Evaluation Form, and x-ray

NA

1 year

NCT01459640

10

Royan Institute

(Tehran, Iran)

40

Randomized

triple-blinded

Autologous BMSCs

WOMAC, VAS, and MRI

NA

6 months

NCT01504464

11

Red de Terapia Celular (Barcelona, Spain)

12

Non- randomized open-label

Autologous BMSCs (40 million)

VAS, Oswestry disability index, and SF-36 life quality

NA

2 years

NCT01183728

12

Royan Institute

6

Non-randomized open-label

BMSCs

WOMAC, VAS, SF-36, and MRI

NA

1 year

NCT01207661

13

Royan Institute

6

Non-randomized open-label

Autologous BMSCs

VAS, WOMAC, x-ray, and MRI

NA

6 months

NCT01436058

14

Royan Institute

6

Non-randomized open-label

Autologous BMSCs

VAS, WOMAC, Harris Hip Score questionnaire, x- ray, and MRI

NA

6 months

NCT01500811

15

Stempeutics

Research

(Bangalore, India)

60

Randomized

double-blind

Allogeneic BMSCs (25,

50, 75, and 150 million)

VAS, WOMAC, ICOAP, x-ray,

and MRI

NA

2 years

NCT01453738

16

University

of Marseille

(Marseille, France)

50

Open-label

Autologous BMSCs

IKS and ICRS

NA

1 year

NCT01159899

17

Stempeutics

Research

Malaysia Sdn. Bhd

(Malaysia)

72

Randomized

double-blind

Allogeneic BMSCs (25

and 50 million)

VAS, WOMAC, ICOAP, x-ray,

and MRI

NA

2 years

NCT01448434

18

Cairo University

(Egypt)

25

Open-label

Autologous BMSCs

Clinical scoring, x-ray, and

MRI

NA

1 year

NCT00891501

19

Royan Institute

6

Open-label

Autologous BMSCs

Pain, knee cartilage defects

NA

1 year

NCT00850187

20

Banc de Sang i

Teixits (Barcelona,

Spain)

15

Open-label

Autologous BMSCs (40

million)

VAS, HAQ, SF-36, and MRI

NA

1 year

NCT01227694

21

Mesoblast

(Melbourne,

Australia)

24

Randomized

double-blind

MSB-CAR001

VAS, KOOS, SF-36, x-ray, and

MRI

NA

2 years

NCT01088191

  1. BM-MSC, bone marrow-derived mesenchymal stem cell; BMSC, bone marrow stromal cell; HAQ, Health Assessment Questionnaire; HPE, histopathological evaluation; ICOAP, Intermittent and Constant Osteoarthritis Pain; ICRS, International Cartilage Repair Society; IKDC, International Knee Documentation Committee; IKS, International Knee Score; IRB, institutional review board; KOOS, Knee and Osteoarthritis Outcome Score; MRI, magnetic resonance imaging; NA, not applicable; RHSSK, Lysholm and Revised Hospital for Special Surgery Knee; SF-36, Short Form Health Survey-36; VAS, Visual Analogue Scale; WOMAC, Western Ontario and McMaster Universities (Osteoarthritis Index).